Search Results 21-30 of 13481 for metrorrhagia
Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might ...
The purpose of this study is to determine if the complete clinical response rate of patients with Stage I-IIIB (cT1-3, N0-1, M0) rectal cancer being treated ...
About this study. The purpose pf this study is to identify the individual contribution of the pronator quadratus and pronator teres during various forearm ...
About this study. The purpose of this research is to monitor body composition changes with wearable devices in patients who have been identified as high ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
The purpose of this study is to analyze the apparent diffusion coefficient (ADC) from Diffusion-Weighted (DWI) in patients before, during the second week of and ...
Patients transferred in to an UPSTREAM hospital are eligible for inclusion, but the timing for OAP agent administration and diagnostic catheterization begin ...
Rochester, Minn. Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to ...
Mayo Clinic researcher Arthur Beyder, M.D., Ph.D., studies motility at the molecular level to discover new treatments for functional GI disorders.
The target organs include brain tissue, the vascular system, but also all other parts of the human body that are accessible to an MR examination with magnetic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.